Antithrombotics in pulmonary hypertension: More work needed before we turn to newer agents

European Respiratory Journal

Volumn 41, Issue 4, 2013, Pages 775-777

  Bertoletti, Laurent ^a,b,c   Delavenne, Xavier ^b,c,d   Montani, David ^e,f,g  

^a UNIVERSITÉ JEAN MONNET   (France)

^b INSERM   (France)

^c HÔPITAL NORD   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f BICÊTRE HOSPITAL   (France)

^g CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; IMATINIB; RIVAROXABAN;

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT;

ANTICOAGULANTS; FEMALE; HEMORRHAGE; HUMANS; HYPERTENSION, PULMONARY; MALE; VITAMIN K;

EID: 84875836115     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00180512     Document Type: Editorial

References (28)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
2. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
3. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006; 130: 545-552.
4. Seferian A, Helal B, Jai?s X, et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J 2012; 40: 75-83.
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
6. Eikelboom JW, Weitz JI. Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?Thromb Haemost 2010; 103: 481-483.
7. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
8. Wynants M, Quarck R, Ronisz A, et al. Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. Eur Respir J 2012; 40: 886-894.
9. Delcroix M, Vonk-Noordegraaf A, Fadel E, et al. Vascular and right ventricular remodeling in chronic thromboembolic pulmonary hypertension. Eur Respir J 2013; 41: 224-232.
10. Jenkins D, Mayer E, Screaton N, et al. State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management. Eur Respir Rev 2012; 21: 32-39.
11. Miniati M, Fiorillo C, Becatti M, et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 2010; 181: 992-996.
12. Kawut SM, Bagiella E, Lederer DJ, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011; 123: 2985-2993.
13. Henkens IR, Hazenoot T, Boonstra A, et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 2013; 41: 872-878.
14. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3: 692-694.
15. Hoeper MM, Barst R, Galie N, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Eur Respir J 2012; 40: Suppl. 56, 583s.
16. Miller DP, Gomberg-Maitland M, Humbert M. Survivor bias and risk assessment. Eur Respir J 2012; 40: 530-532.
17. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124: 1973-1981.
18. Nieto JA, Solano R, Ruiz-Ribó MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J ThrombHaemost 2010; 8: 1216-1222.
19. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39: 945-955.
20. Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993; 329: 696-702.
21. Delcroix M, Naeije R. Optimising the management of pulmonary arterial hypertension patients: emergency treatments. Eur Respir Rev 2010; 19: 204-211.
22. Savale L, Chaumais MC, Cottin V, et al. Pulmonary hypertension associatedwith benfluorex exposure. Eur Respir J 2012; 40: 1164-1172.
23. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
24. Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
25. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
26. Bertoletti L, Delavenne X, Montani D, et al. Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants. Eur Respir J 2012; 40: Suppl. 56, 274s.
27. Delavenne X, Moracchini J, Laporte S, et al. UPLC MS/MS assay for routine quantification of dabigatran-A direct thrombin inhibitor-in human plasma. J Pharm Biomed Anal 2012; 58: 152-156.
28. Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 2010; 8: 621-626.